635 related articles for article (PubMed ID: 16703509)
1. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination.
Sun W; Nisalak A; Gettayacamin M; Eckels KH; Putnak JR; Vaughn DW; Innis BL; Thomas SJ; Endy TP
J Infect Dis; 2006 Jun; 193(12):1658-65. PubMed ID: 16703509
[TBL] [Abstract][Full Text] [Related]
2. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
Simmons M; Burgess T; Lynch J; Putnak R
Virology; 2010 Jan; 396(2):280-8. PubMed ID: 19913867
[TBL] [Abstract][Full Text] [Related]
3. Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines.
Sun W; Eckels KH; Putnak JR; Lyons AG; Thomas SJ; Vaughn DW; Gibbons RV; Fernandez S; Gunther VJ; Mammen MP; Statler JD; Innis BL
J Infect Dis; 2013 Mar; 207(5):700-8. PubMed ID: 23225894
[TBL] [Abstract][Full Text] [Related]
4. Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes.
Putnak R; Fuller J; VanderZanden L; Innis BL; Vaughn DW
Am J Trop Med Hyg; 2003 Apr; 68(4):469-76. PubMed ID: 12875299
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.
Robert Putnak J; Coller BA; Voss G; Vaughn DW; Clements D; Peters I; Bignami G; Houng HS; Chen RC; Barvir DA; Seriwatana J; Cayphas S; Garçon N; Gheysen D; Kanesa-Thasan N; McDonell M; Humphreys T; Eckels KH; Prieels JP; Innis BL
Vaccine; 2005 Aug; 23(35):4442-52. PubMed ID: 16005749
[TBL] [Abstract][Full Text] [Related]
6. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
Blaney JE; Matro JM; Murphy BR; Whitehead SS
J Virol; 2005 May; 79(9):5516-28. PubMed ID: 15827166
[TBL] [Abstract][Full Text] [Related]
7. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.
Blaney JE; Sathe NS; Hanson CT; Firestone CY; Murphy BR; Whitehead SS
Virol J; 2007 Feb; 4():23. PubMed ID: 17328799
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a live attenuated tetravalent candidate dengue vaccine in naïve and previously infected cynomolgus macaques.
Koraka P; Benton S; van Amerongen G; Stittelaar KJ; Osterhaus AD
Vaccine; 2007 Jul; 25(29):5409-16. PubMed ID: 17560694
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.
Kitchener S; Nissen M; Nasveld P; Forrat R; Yoksan S; Lang J; Saluzzo JF
Vaccine; 2006 Feb; 24(9):1238-41. PubMed ID: 16213632
[TBL] [Abstract][Full Text] [Related]
10. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
[TBL] [Abstract][Full Text] [Related]
11. Chimeric dengue type 2/type 1 viruses induce immune responses in cynomolgus monkeys.
Butrapet S; Rabablert J; Angsubhakorn S; Wiriyarat W; Huang C; Kinney R; Punyim S; Bhamarapravati N
Southeast Asian J Trop Med Public Health; 2002 Sep; 33(3):589-99. PubMed ID: 12693596
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys.
Blair PJ; Kochel TJ; Raviprakash K; Guevara C; Salazar M; Wu SJ; Olson JG; Porter KR
Vaccine; 2006 Feb; 24(9):1427-32. PubMed ID: 16214271
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of interferences between dengue vaccine serotypes in a monkey model.
Guy B; Barban V; Mantel N; Aguirre M; Gulia S; Pontvianne J; Jourdier TM; Ramirez L; Gregoire V; Charnay C; Burdin N; Dumas R; Lang J
Am J Trop Med Hyg; 2009 Feb; 80(2):302-11. PubMed ID: 19190230
[TBL] [Abstract][Full Text] [Related]
14. Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.
Barban V; Mantel N; De Montfort A; Pagnon A; Pradezynski F; Lang J; Boudet F
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593041
[TBL] [Abstract][Full Text] [Related]
15. Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins.
Bernardo L; Hermida L; Martin J; Alvarez M; Prado I; López C; Martínez R; Rodríguez-Roche R; Zulueta A; Lazo L; Rosario D; Guillén G; Guzmán MG
Arch Virol; 2008; 153(5):849-54. PubMed ID: 18299795
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children.
Sabchareon A; Lang J; Chanthavanich P; Yoksan S; Forrat R; Attanath P; Sirivichayakul C; Pengsaa K; Pojjaroen-Anant C; Chambonneau L; Saluzzo JF; Bhamarapravati N
Pediatr Infect Dis J; 2004 Feb; 23(2):99-109. PubMed ID: 14872173
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.
Liu G; Song L; Beasley DW; Putnak R; Parent J; Misczak J; Li H; Reiserova L; Liu X; Tian H; Liu W; Labonte D; Duan L; Kim Y; Travalent L; Wigington D; Weaver B; Tussey L
Clin Vaccine Immunol; 2015 May; 22(5):516-25. PubMed ID: 25761459
[TBL] [Abstract][Full Text] [Related]
18. Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate.
Anderson KB; Gibbons RV; Edelman R; Eckels KH; Putnak RJ; Innis BL; Sun W
J Infect Dis; 2011 Aug; 204(3):442-50. PubMed ID: 21742844
[TBL] [Abstract][Full Text] [Related]
19. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
[TBL] [Abstract][Full Text] [Related]
20. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
